Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $631.7M | $1,111.1M | ($758.8M) | $2,164.5M | $2,678.5M | $3,529.2M | $3,962.2M | $3,789.8M | $4,010.2M | $4,524.0M | $15.3B | $22.2B | $17.6B | $14.1B | $8,200.0M | $4,287.0M | $7,029.0M | $7,406.0M | $7,330.0M | $7,605.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Gilead Sciences, Inc.'s last 12-month Operating Income is $8,384.0M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Gilead Sciences, Inc.'s Operating Income growth was 1.5%. The average annual Operating Income growth rates for Gilead Sciences, Inc. have been 22.5% over the past three years, 14.1% over the past five years.
Over the last year, Gilead Sciences, Inc.'s Operating Income growth was 1.5%, which is higher than industry growth of 0.0%. It indicates that Gilead Sciences, Inc.'s Operating Income growth is Good.